The stock price of KPM Tech reached the upper limit (the top of the daily price restriction range) on the morning of the 13th.
According to the Korea Exchange, as of 10 a.m. on this day, KPM Tech was trading at 319 won, up 73 won (29.67%) from the previous day. This is interpreted as a reaction to the Ministry of Food and Drug Safety granting approval for VIVACON Pharmaceuticals' non-narcotic pain reliever, Anapraju (Ophiranzerin), the day before.
Previously, KPM Tech entered into a transfer agreement for the development and implementation rights of Ophiranzerin from VIVACON Pharmaceuticals. At the same time, VIVACON Pharmaceuticals was also trading at 11,310 won, up 2,610 won (30%).
Until now, the only pain relievers that could be used for moderate to severe pain were opioid medications. However, as issues with opioids, such as fentanyl, have emerged as a social problem, the demand for non-narcotic pain relievers has increased. In this context, Anapraju has been released as the world's first non-narcotic and non-steroidal anti-inflammatory pain reliever.